Table 4.
Univariate proportional-hazards regression analysis of cofactors on overall survival in glioblastoma patients with conventionally fractionated radiotherapy.
| Cofactors | HR | 95% CI | p value |
|---|---|---|---|
| Karnofsky performance status > 80 | 1.01 | 0.61–2.04 | 0.73 |
| Peripheral versus central | 1.05 | 0.59–1.85 | 0.88 |
| MGMT promoter methylation | 0.93 | 0.67–1.29 | 0.66 |
| Biopsy versus surgical resection | 0.63 | 0.30–1.51 | 0.29 |
| Gross total resection versus subtotal resection | 0.97 | 0.52–1.80 | 0.92 |
| Temozolomide therapy | 0.49 | 0.27–0.90 | 0.02 |
| Mean IL ventricle dose ≥ 40 Gy | 0.64 | 0.34–1.21 | 0.17 |
| Mean CL ventricle dose ≥ 40 Gy | 0.80 | 0.31–2.05 | 0.65 |
| Mean IL SVZ dose ≥ 40 Gy | 0.65 | 0.34–1.24 | 0.10 |
| Mean CL SVZ dose ≥ 30 Gy | 1.53 | 0.36–6.43 | 0.56 |
| Mean IL DG dose ≥ 40 Gy | 1.24 | 0.61–2.32 | 0.50 |
| Mean CL DG dose ≥ 30 Gy | 1.21 | 0.16–3.09 | 0.85 |
CI: confidence interval; HR: hazard ratio; IL: ipsilateral; CL: contralateral; SVZ: subventricular zone; DG: dentate gyrus; Gy: gray; MGMT: O-6-methylguanine methyltransferase; RT: radiation therapy.